Ninjurin-1 mediates cell lysis and detrimental inflammation of PANoptosis during influenza A virus infection.

Ninjurin-1 mediates cell lysis and detrimental inflammation of PANoptosis during influenza A virus infection.

Publication date: Sep 23, 2025

Influenza A virus (IAV) induces ZBP1-mediated PANoptosis, a form of lytic inflammatory cell death characterized by concurrent activation of the pyroptosis, necroptosis and apoptosis pathways. Ninjurin-1 (NINJ1) is a recently identified mediator of plasma membrane rupture but functions diversely in different types of cell death. However, little is known about the role of NINJ1 in IAV-induced PANoptosis and viral pneumonia. Here, we report that IAV infection triggered an increase in the expression of NINJ1, which then oligomerized and mediated cell lysis in infected macrophages. The deficiency of NINJ1 prevented plasma membrane rupture and the release of DAMPs and IL-1β without affecting the progression of cell death. Activation of any single PANoptosis pathway was sufficient to trigger the oligomerization of NINJ1 and robust cell lysis. Accordingly, only when all PANoptosis pathways were concurrently blocked could the oligomerization of NINJ1, cell death, and cell rupture be prevented. Ablation of NINJ1 in vivo also alleviated IAV-induced lung injury and mortality. Furthermore, we revealed an association between NINJ1 upregulation and poor outcomes in patients with COVID-19. Collectively, our findings indicate a pivotal role of NINJ1 in the immunopathology of IAV infection and its potential as a bioindicator of disease severity and prognosis in viral pneumonia and viral sepsis.

Open Access PDF

Concepts Keywords
Bioindicator Animals
Covid COVID-19
Necroptosis Female
Pneumonia Humans
Viral Inflammation
Influenza A virus
Influenza, Human
Interleukin-1beta
Interleukin-1beta
Macrophages
Male
Mice
Mice, Knockout
Necroptosis
Nerve Growth Factors
Nerve Growth Factors
NINJ1 protein, human
Ninj1 protein, mouse
Orthomyxoviridae Infections
SARS-CoV-2

Semantics

Type Source Name
disease IDO cell
disease MESH inflammation
drug DRUGBANK Influenza A virus
pathway REACTOME Pyroptosis
pathway KEGG Necroptosis
pathway REACTOME Apoptosis
disease IDO role
disease MESH viral pneumonia
disease MESH infection
pathway REACTOME Release
disease MESH lung injury
disease MESH COVID-19
disease MESH sepsis
disease MESH influenza
disease MESH virus infection
disease MESH death
pathway REACTOME Signal Transduction
disease IDO host
disease IDO replication
disease IDO process
disease MESH Respiratory Diseases
disease IDO pathogen
disease MESH Emerging Infectious Diseases
drug DRUGBANK Coenzyme M
disease MESH dissociation
pathway KEGG Ferroptosis
drug DRUGBANK Silver
disease IDO production
drug DRUGBANK Aspartame
disease MESH viral load
drug DRUGBANK Glycine
drug DRUGBANK L-Lysine
drug DRUGBANK Proline
drug DRUGBANK Dimethyl sulfoxide
pathway KEGG Tight junction
disease MESH stunted growth
disease MESH hydrocephaly
disease MESH ataxia
drug DRUGBANK Dimercaprol
disease MESH pneumonia
disease MESH critically ill
disease MESH necrosis
pathway REACTOME Influenza Infection
disease IDO susceptibility
drug DRUGBANK Acetate ion
drug DRUGBANK Methylergometrine
drug DRUGBANK Trichloroethylene
drug DRUGBANK Tromethamine
drug DRUGBANK Neon
drug DRUGBANK Puromycin
disease IDO assay
disease IDO reagent
drug DRUGBANK Collagenase clostridium histolyticum
disease IDO blood
disease MESH Chronic Diseases
pathway REACTOME Regulated Necrosis
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Endoplasmic reticulum stress
disease MESH Yersinia infection
pathway KEGG Yersinia infection
disease MESH cytokine storm
disease IDO virulence
disease MESH shock
disease MESH coronavirus infection
disease MESH DFNA5
pathway REACTOME Reproduction
disease MESH Orthomyxoviridae Infections

Original Article

(Visited 10 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *